Please enable JavaScript to continue using this application.

Compare $CGON vs $GRAL | Chartloom

Compare

$CGON vs $GRAL

CG Oncology Inc · Grail Inc

CGON

CG Oncology Inc

GRAL

Grail Inc

Compare $CGON vs $GRAL

Comparing CG Oncology Inc and Grail Inc

CGONCG Oncology Inc

GRALGrail Inc

CGONCG Oncology Inc

Market cap

$5.63B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

135.78x

Rev growth (TTM)

1030.3%

YTD performance

52.7%

52W performance

56.8%

FCF yield

-3.2%

GRALGrail Inc

Market cap

$6.03B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

29.71x

Rev growth (TTM)

23.1%

YTD performance

58.2%

52W performance

123.8%

FCF yield

-4.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CGON

GRAL

Detailed metrics comparison

CGON

CG Oncology Inc

GRAL

Grail Inc

Market Cap

CGON$5.63B

GRAL$6.03B

Enterprise Value

CGON$5.61B

GRAL$5.98B

Price

CGON$63.82

GRAL$140.58

P/E Ratio

CGONN/A

GRALN/A

P/S Ratio

CGON903.81x

GRAL36.51x

EV/Sales

CGON901.14x

GRAL36.17x

EV/EBITDA

CGON0.00x

GRAL0.00x

P/B Ratio

CGON5.80x

GRAL2.52x

P/FCF Ratio

CGONN/A

GRALN/A

EV/FCF

CGON-31.29x

GRAL-20.19x

PEG Ratio

CGONN/A

GRALN/A

Forward P/E (NTM)

CGONN/A

GRALN/A

Forward P/S (NTM)

CGON135.78x

GRAL29.71x

Revenue (TTM)

CGON$6M

GRAL$165M

Revenue Growth (YoY)

CGON1030.3%

GRAL23.1%

Forward Rev Growth

CGON1916.0%

GRAL25.3%

Gross Margin (TTM)

CGON-85.2%

GRAL49.7%

Operating Margin (TTM)

CGON0.0%

GRAL0.0%

EBITDA Margin (TTM)

CGON-4008.7%

GRAL-229.0%

Net Margin (TTM)

CGON-3602.7%

GRAL-236.9%

FCF Margin (TTM)

CGON-2879.6%

GRAL-179.2%

Net Income (TTM)

CGON$-224M

GRAL$-392M

FCF (TTM)

CGON$-179M

GRAL$-296M

EPS (TTM)

CGON-$2.54

GRAL-$9.08

ROE (TTM)

CGON-2520.0%

GRAL-1588.0%

ROA (TTM)

CGON-2398.0%

GRAL-1402.0%

ROIC (TTM)

CGON-2512.0%

GRAL-1588.0%

Cash

CGON$20M

GRAL$56M

Debt

CGON$3M

GRAL$0

Net Cash/Debt

CGON$17M

GRAL$56M

Current Ratio (TTM)

CGON22.22x

GRAL10.95x

Quick Ratio (TTM)

CGON21.78x

GRAL10.55x

Debt/Equity (TTM)

CGON0.00x

GRAL0.00x

Debt/Assets (TTM)

CGON0.0%

GRAL0.0%

Interest Coverage (TTM)

CGONN/A

GRALN/A

Net Debt/EBITDA (TTM)

CGON0.00x

GRAL0.00x

Beta

CGON0.25

GRAL2.04

52W Performance

CGON56.8%

GRAL123.8%

YTD Performance

CGON52.7%

GRAL58.2%

% from 52W High

CGON-21.2%

GRAL-15.6%

% from 52W Low

CGON78.3%

GRAL238.7%

Asset Turnover (TTM)

CGON0.01x

GRAL0.06x

FCF Yield (TTM)

CGON-3.2%

GRAL-4.9%

Earnings Yield (TTM)

CGON-4.0%

GRAL-6.5%

Dividend Yield (TTM)

CGONN/A

GRALN/A

Rule of 40

CGON-1,849.3

GRAL-156.1

EV/GP/RG

CGONN/A

GRAL2.75

Ticker research

View CGON research View GRAL research

Metric	CGON CG Oncology Inc	GRAL Grail Inc
Market & Valuation
Market Cap	$5.63B	$6.03B
Enterprise Value	$5.61B	$5.98B
Price	$63.82	$140.58
P/E Ratio	N/A	N/A
P/S Ratio	903.81x	36.51x
EV/Sales	901.14x	36.17x
EV/EBITDA	0.00x	0.00x
P/B Ratio	5.80x	2.52x
P/FCF Ratio	N/A	N/A
EV/FCF	-31.29x	-20.19x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	135.78x	29.71x
Revenue & Growth
Revenue (TTM)	$6M	$165M
Revenue Growth (YoY)	1030.3%	23.1%
Forward Rev Growth	1916.0%	25.3%
Profitability
Gross Margin (TTM)	-85.2%	49.7%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-4008.7%	-229.0%
Net Margin (TTM)	-3602.7%	-236.9%
FCF Margin (TTM)	-2879.6%	-179.2%
Net Income (TTM)	$-224M	$-392M
FCF (TTM)	$-179M	$-296M
EPS (TTM)	-$2.54	-$9.08
ROE (TTM)	-2520.0%	-1588.0%
ROA (TTM)	-2398.0%	-1402.0%
ROIC (TTM)	-2512.0%	-1588.0%
Financial Health
Cash	$20M	$56M
Debt	$3M	$0
Net Cash/Debt	$17M	$56M
Current Ratio (TTM)	22.22x	10.95x
Quick Ratio (TTM)	21.78x	10.55x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.25	2.04
52W Performance	56.8%	123.8%
YTD Performance	52.7%	58.2%
% from 52W High	-21.2%	-15.6%
% from 52W Low	78.3%	238.7%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.06x
FCF Yield (TTM)	-3.2%	-4.9%
Earnings Yield (TTM)	-4.0%	-6.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,849.3	-156.1
EV/GP/RG	N/A	2.75
Ticker research	View CGON research	View GRAL research

Valuation

P/S Ratio

GRAL

36.51x

CGON

903.81x

EV/FCF

CGON

-31.29x

GRAL

-20.19x

Growth & revenue

Revenue Growth TTM

CGON

1030.3%

GRAL

23.1%

Forward Revenue Growth

CGON

1916.0%

GRAL

25.3%

Profitability & performance

Gross Margin

GRAL

49.7%

CGON

-85.2%

ROE

GRAL

-1588.0%

CGON

-2520.0%

FCF Yield %

CGON

-3.2%

GRAL

-4.9%

52-Week Performance

GRAL

123.8%

CGON

56.8%

Detailed metrics comparison

CGON

CG Oncology Inc

GRAL

Grail Inc

Market Cap

CGON$5.63B

GRAL$6.03B

Enterprise Value

CGON$5.61B

GRAL$5.98B

Price

CGON$63.82

GRAL$140.58

P/E Ratio

CGONN/A

GRALN/A

P/S Ratio

CGON903.81x

GRAL36.51x

EV/Sales

CGON901.14x

GRAL36.17x

EV/EBITDA

CGON0.00x

GRAL0.00x

P/B Ratio

CGON5.80x

GRAL2.52x

P/FCF Ratio

CGONN/A

GRALN/A

EV/FCF

CGON-31.29x

GRAL-20.19x

PEG Ratio

CGONN/A

GRALN/A

Forward P/E (NTM)

CGONN/A

GRALN/A

Forward P/S (NTM)

CGON135.78x

GRAL29.71x

Revenue (TTM)

CGON$6M

GRAL$165M

Revenue Growth (YoY)

CGON1030.3%

GRAL23.1%

Forward Rev Growth

CGON1916.0%

GRAL25.3%

Gross Margin (TTM)

CGON-85.2%

GRAL49.7%

Operating Margin (TTM)

CGON0.0%

GRAL0.0%

EBITDA Margin (TTM)

CGON-4008.7%

GRAL-229.0%

Net Margin (TTM)

CGON-3602.7%

GRAL-236.9%

FCF Margin (TTM)

CGON-2879.6%

GRAL-179.2%

Net Income (TTM)

CGON$-224M

GRAL$-392M

FCF (TTM)

CGON$-179M

GRAL$-296M

EPS (TTM)

CGON-$2.54

GRAL-$9.08

ROE (TTM)

CGON-2520.0%

GRAL-1588.0%

ROA (TTM)

CGON-2398.0%

GRAL-1402.0%

ROIC (TTM)

CGON-2512.0%

GRAL-1588.0%

Cash

CGON$20M

GRAL$56M

Debt

CGON$3M

GRAL$0

Net Cash/Debt

CGON$17M

GRAL$56M

Current Ratio (TTM)

CGON22.22x

GRAL10.95x

Quick Ratio (TTM)

CGON21.78x

GRAL10.55x

Debt/Equity (TTM)

CGON0.00x

GRAL0.00x

Debt/Assets (TTM)

CGON0.0%

GRAL0.0%

Interest Coverage (TTM)

CGONN/A

GRALN/A

Net Debt/EBITDA (TTM)

CGON0.00x

GRAL0.00x

Beta

CGON0.25

GRAL2.04

52W Performance

CGON56.8%

GRAL123.8%

YTD Performance

CGON52.7%

GRAL58.2%

% from 52W High

CGON-21.2%

GRAL-15.6%

% from 52W Low

CGON78.3%

GRAL238.7%

Asset Turnover (TTM)

CGON0.01x

GRAL0.06x

FCF Yield (TTM)

CGON-3.2%

GRAL-4.9%

Earnings Yield (TTM)

CGON-4.0%

GRAL-6.5%

Dividend Yield (TTM)

CGONN/A

GRALN/A

Rule of 40

CGON-1,849.3

GRAL-156.1

EV/GP/RG

CGONN/A

GRAL2.75

Ticker research

View CGON research View GRAL research

Metric	CGON CG Oncology Inc	GRAL Grail Inc
Market & Valuation
Market Cap	$5.63B	$6.03B
Enterprise Value	$5.61B	$5.98B
Price	$63.82	$140.58
P/E Ratio	N/A	N/A
P/S Ratio	903.81x	36.51x
EV/Sales	901.14x	36.17x
EV/EBITDA	0.00x	0.00x
P/B Ratio	5.80x	2.52x
P/FCF Ratio	N/A	N/A
EV/FCF	-31.29x	-20.19x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	135.78x	29.71x
Revenue & Growth
Revenue (TTM)	$6M	$165M
Revenue Growth (YoY)	1030.3%	23.1%
Forward Rev Growth	1916.0%	25.3%
Profitability
Gross Margin (TTM)	-85.2%	49.7%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-4008.7%	-229.0%
Net Margin (TTM)	-3602.7%	-236.9%
FCF Margin (TTM)	-2879.6%	-179.2%
Net Income (TTM)	$-224M	$-392M
FCF (TTM)	$-179M	$-296M
EPS (TTM)	-$2.54	-$9.08
ROE (TTM)	-2520.0%	-1588.0%
ROA (TTM)	-2398.0%	-1402.0%
ROIC (TTM)	-2512.0%	-1588.0%
Financial Health
Cash	$20M	$56M
Debt	$3M	$0
Net Cash/Debt	$17M	$56M
Current Ratio (TTM)	22.22x	10.95x
Quick Ratio (TTM)	21.78x	10.55x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.25	2.04
52W Performance	56.8%	123.8%
YTD Performance	52.7%	58.2%
% from 52W High	-21.2%	-15.6%
% from 52W Low	78.3%	238.7%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.06x
FCF Yield (TTM)	-3.2%	-4.9%
Earnings Yield (TTM)	-4.0%	-6.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,849.3	-156.1
EV/GP/RG	N/A	2.75
Ticker research	View CGON research	View GRAL research